Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm Study, Evaluating the Immunogenicity and Safety of HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

NCT03934736 is registered in ClinicalTrials.gov with Dynavax Technologies Corporation as lead sponsor.

NCT NCT03934736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03934736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm Study, Evaluating the Immunogenicity and Safety of HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
Lead sponsor
Dynavax Technologies Corporation
Phase
Phase 1
Overall status
Completed
Start date
April 22, 2019
Completion date
September 15, 2021
Enrollment
119 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease on hemodialysis (diagnosis)